Respiratory syncytial virus (RSV) polypeptide with immunogenicity

By designing recombinant RSV polypeptides, using cysteine ​​to replace mutations to form disulfide bonds and multimerization domains, locking the pre-fusion conformation, the problem of insufficient F protein antigen stability and immunogenicity in existing RSV vaccines is solved, and the problem of insufficient F protein antigen stability and immunogenicity in existing RSV vaccines is achieved. Efficient antibody response and vaccine effects.

CN119019514APending Publication Date: 2024-11-26JIANGSU RECBIO TECH CO LTD +1
View PDF 0 Cites 3 Cited by

Patent Information

Application Number
CN202410664376.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-01-19
Filing Date
2024-05-27
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The selection of antigens in existing RSV vaccines is mainly focused on F proteins, especially F proteins in pre-fusion conformations. Although there have been a lot of research, its safety and effectiveness as a vaccine still faces huge challenges, lacking stability and Enhanced immunogenicity.

Method used

A recombinant respiratory syncytial virus (RSV) polypeptide is designed that contains the RSV F protein recombinant ectodomain, which forms disulfide bonds by introducing cysteine ​​substitution mutations, stabilizes the protein configuration and oligomerization state, and binds to the multimerization structure. domain, locking in pre-fusion conformation, enhancing expression and immunogenicity.

Benefits of technology

The stabilization and multimerization of RSV F protein was achieved, and its expression volume and immunogenicity were improved, ensuring effective neutralizing antibody response and binding antibody response to respiratory syncytial virus, improving the safety and effectiveness of the vaccine. sex.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019514A_ABST
    Figure CN119019514A_ABST
Patent Text Reader

Abstract

The invention provides a respiratory syncytial virus (RSV) polypeptide with immunogenicity, and relates to the technical field of biological medicines. The stable pre-fusion F protein is successfully constructed and expressed by utilizing an extracellular domain of RSV F protein recombination, the stability of the pre-fusion conformation F protein is enhanced through mutation design of different disulfide bonds, and the obtained antigen and the vaccine prepared from the antigen are high in expression quantity, good in stability and high in immunogenicity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application belongs to the field of biomedicine technology, and in particular relates to an immunogenic respiratory syncytial virus (RSV) polypeptide, a preparation method thereof, and an application thereof in preparing a vaccine for preventing RSV infection. Background Art

[0002] Respiratory viral infections are one of the most important public health burdens worldwide, resulting in millions of hospitalizations worldwide each year. Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory tract infections in children under 2 years of age and adults over 65 years of age. Despite the serious harm caused by respiratory diseases caused by RSV infection, there is currently no effective treatment or preventive vaccine specifically for RSV. Looking at the RSV vaccines that have entered the clinical stage worldwide, the main research and development directions are focused on live attenuated vaccines, recombinant subunit vaccines, and viral vector vaccines. RSV vaccine development is mainly aimed at three target groups, including infants, pregnant women, and the elderly (≥60 years old). For infants under 6 months of age, passive immune protection is mainly achieved through mAbs, or passive protection is obtained by antibody transfer through the placenta after pregnant women are vaccinated with RSV vaccines; for infants older than 6 months of age, protection can be obtained through active immunization with live attenuated RSV vaccines; for pregnant women and the elderly, RSV vaccine development is mainly based on subunit vaccines.

[0003] The selection of mainstream vaccine antigens is mainly focused on F protein, especially the F protein in the prefusion conformation (PreF). Compared with the F protein in the postfusion conformation, the F protein in the prefusion conformation can expose more potential epitopes with neutralizing activity, such as epitope Φ and epitope V that only exist in PreF. Antibodies generated against epitope Φ and epitope V have excellent neutralizing activity. After binding to the F protein in the prefusion conformation, they can block the viral membrane fusion mediated by the conformational change of the F protein. Although there have been a lot of studies on the stability of the prefusion conformation of RSV F protein, its safety and effectiveness as a vaccine still face huge challenges.

[0004] Therefore, providing an RSV antigen with high safety, enhanced immunogenicity and improved stability, and a vaccine containing the same has become a technical problem that those skilled in the art urgently need to solve. Summary of the invention

[0005] In order to solve the above technical problems, the present invention provides a respiratory syncytial virus (RSV) polypeptide with immunogenicity.

[0006] On the one hand, the present invention discloses a recombinant respiratory syncytial virus (RSV) polypeptide, comprising a recombinant extracellular domain of RSV F protein, corresponding to amino acid residues 26-513 of the wild-type RSV F protein sequence shown in SEQ ID NO: 1, wherein the recombinant extracellular domain comprises at least 3 types of cysteine ​​substitution mutations, wherein the cysteine ​​substitution mutations form disulfide bonds between the introduced cysteine ​​residues, and the disulfide bonds are used to stabilize the conformation or oligomeric state of the protein, such as the pre-fusion conformation, wherein one type is an intermolecular cysteine ​​substitution mutation, selected from 1 or 2 pairs of V144C+I407C, K75C+E218C, S146C+N460C and A149C+Y458C. Another type is an N-type cysteine ​​substitution mutation, wherein the site of the N-type cysteine ​​substitution is between residues 1-300 of the wild-type RSV F protein amino acid sequence, preferably between positions 137 and 216, including one or two pairs of cysteine ​​substitutions; the third type is a C-type cysteine ​​substitution mutation, wherein the site of the C-type cysteine ​​substitution is between residues 320-500 of the wild-type RSV F protein amino acid sequence, preferably between positions 460 and 500, including one or two pairs of cysteine ​​substitutions.

[0007] The N-type cysteine ​​substitution mutation described in the technical solution of the present invention refers to a pair in which one of the mutation sites is between 137 and 216 of the F protein, and the C-type cysteine ​​substitution mutation refers to a pair in which one of the mutation sites is between 460 and 500 of the F protein.

[0008] The one mutation site in the technical solution of the present invention is between 137 and 216 of the F protein, which refers to I148C+Y286C, S55C+L188C, H159C+I291C or G151C+I288C.

[0009] The one mutation site described in the technical solution of the present invention is between 460 and 500 of the F protein, which refers to K399C+S485C, S443C+S466C, T323C+I475C, I332C+P480C or F387C+I492C.

[0010] The present invention discloses an immunogenic respiratory syncytial virus (RSV) polypeptide, comprising a recombinant extracellular domain of RSV F protein, corresponding to amino acid residues 26-513 of the wild-type RSV F protein sequence shown in SEQ ID NO: 1, wherein the recombinant extracellular domain comprises the following combination of cysteine ​​substitution mutations:

[0011] A. Intermolecular cysteine ​​substitution mutations are selected from one or two pairs of V144C+I407C, K75C+E218C, S146C+N460C and A149C+Y458C;

[0012] B, N-type cysteine ​​substitution mutations, one of which is at positions 137 to 216 of the F protein;

[0013] C. Class C cysteine ​​substitution mutations, one of which is located between positions 460 and 500 of the F protein.

[0014] In the technical solution of the present invention, the one mutation site at positions 137 to 216 of the F protein is selected from one or two pairs of I148C+Y286C, S55C+L188C, H159C+I291C and G151C+I288C; wherein the one mutation site at positions 460 to 500 of the F protein refers to K399C+S485C, S443C+S466C, T323C+I475C, I332C+P480C or F387C+I492C.

[0015] The invention discloses a recombinant respiratory syncytial virus (RSV) polypeptide, comprising a recombinant extracellular domain of an RSV F protein, corresponding to amino acid residues 26-513 of a wild-type RSV F protein sequence shown in SEQ ID NO: 1, and having cysteine ​​mutations K75C+E218C and / or V144C+I407C compared to the wild-type RSV F protein.

[0016] The invention discloses a recombinant respiratory syncytial virus (RSV) polypeptide, which has cysteine ​​mutations I148C+Y286C or S55C+L188C compared with wild-type RSV F protein.

[0017] The invention discloses a recombinant respiratory syncytial virus (RSV) polypeptide, which has cysteine ​​mutations K399C+S485C or F387C+I492C compared with wild-type RSV F protein.

[0018] The polypeptide disclosed in the present invention, wherein the recombinant extracellular domain comprises one of the following combinations of cysteine ​​substitution mutations:

[0019] A. V144C+I407C, K75C+E218C, I148C+Y286C, and F387C+I492C;

[0020] B. V144C+I407C, I148C+Y286C, S55C+L188C, and F387C+I492C;

[0021] C.K75C+E218C, I148C+Y286C, T323C+I475C,

[0022] D.K75C+E218C, I148C+Y286C, F387C+I492C,

[0023] E.K75C+E218C, I148C+Y286C, K399C+S485C,

[0024] F.K75C+E218C, G151C+I288C, K399C+S485C,

[0025] G.K75C+E218C, H159C+I291C, K399C+S485C,

[0026] The polypeptide described in the technical solution of the present invention, wherein the recombinant extracellular domain further comprises a cavity-filling mutation, and the cavity-filling mutation site is selected from one, two, three or four of positions 67, 495, 296 and 190 of the amino acid sequence of the wild-type RSV F protein.

[0027] In some embodiments, the preferred cavity-filling mutation is N67F, and in other embodiments, the preferred cavity-filling mutation is N67F+S190V+V296F+V495L.

[0028] The polypeptide described in the technical solution of the present invention, wherein the recombinant extracellular domain further comprises mutations P102A+I379V+M447V, S46G or G184N that increase the expression amount.

[0029] The recombinant extracellular domain described in the present invention comprises an epitope that is only present in the pre-fusion conformation, and the epitope comprises residues 62-69 and 196-209 of the wild-type RSV F protein sequence shown in SEQ ID NO:1.

[0030] The polypeptide described in the technical solution of the present invention, wherein the recombinant extracellular domain includes a recombinant F2 domain comprising at least amino acid residues 26-105 of RSV F protein and a recombinant F1 domain comprising at least amino acid residues 145-513 of RSV F protein.

[0031] In the polypeptide described in the technical solution of the present invention, the recombinant F2 domain is connected to the recombinant F1 domain directly or through a linker.

[0032] In some embodiments, the recombinant F2 domain and the recombinant F1 domain are connected by a linker, which means that the C-terminus of the F2 domain and the N-terminus of the F1 domain are connected by a linker, for example, residues 106-144 of the recombinant extracellular domain of the F protein are replaced by a linker sequence selected from GGPGGS, GAPEPGE or GGSGGSG.

[0033] In some embodiments, the C-terminus of the polypeptide includes a multimerization domain.

[0034] In some embodiments, the multimerization domain is located at the C-terminus of the recombinant extracellular domain and is directly connected to the C-terminus of the recombinant extracellular domain or connected via a linker sequence.

[0035] In some embodiments, optionally, the linker sequence is GGGSSGS, GSGSG, or a 4-10 amino acid sequence consisting of G and S.

[0036] In some embodiments, wherein the multimerization domain is a trimerization domain, the trimerization domain promotes the formation of a trimer of three F1 / F2 heterodimers.

[0037] In some embodiments, the multimerization domain is a domain that can achieve higher polymerization, such as ferritin that can self-assemble to form twenty-tetramers.

[0038] In some embodiments, the multimerization domain is preferably a foldon domain or a ferritin domain.

[0039] In the present application, "ferritin" refers to the ferritin of Trichoplusia ni or Helicobacter pylori. In the present application, the ferritin of Helicobacter pylori has a single-chain structure. In the present application, the ferritin may be a mutant of the ferritin of Trichoplusia ni or Helicobacter pylori. In the present application, "mutant" generally refers to a sequence that is different from a reference sequence by containing one or more differences (mutations). The difference may be a substitution, deletion or insertion of one or more amino acids. Exemplarily, the amino acid sequence of ferritin used in the present application is ESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFDHAAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYVAEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKS.

[0040] In some embodiments, the recombinant extracellular domain includes the F2 domain or a functionally active fragment thereof and the F1 domain or a functionally active fragment thereof of the RSV F protein.

[0041] In some embodiments, the F2 domain comprises a RSV F protein polypeptide corresponding to amino acids 26-105 of SEQ ID NO:1, and the F1 domain comprises a RSV F protein polypeptide corresponding to amino acids 137-516 of SEQ ID NO:1.

[0042] In some embodiments, the recombinant extracellular domain includes a recombinant F2 domain comprising at least amino acid residues 26-105 of the RSV F protein and a recombinant F1 domain comprising at least amino acid residues 145-513 of the RSV F protein.

[0043] In some embodiments, the recombinant extracellular domain includes a recombinant F2 domain comprising amino acid residues 26-105 of the RSV F protein and a recombinant F1 domain comprising amino acid residues 145-513 of the RSV F protein.

[0044] In some embodiments, the recombinant F2 domain and the recombinant F1 domain are connected via a linker sequence.

[0045] In some embodiments, the recombinant F2 domain and the recombinant F1 domain are connected via a linker sequence of 4-10 amino acid residues consisting of GGGSSGS, GGSG, GGPG, or G and S.

[0046] In some embodiments, the linker sequence of 4-10 amino acid residues composed of G and S can be GGSGGSG.

[0047] In some embodiments, the recombinant extracellular domain includes a recombinant F2 domain comprising at least amino acid residues 26-103 of the RSV F protein and a recombinant F1 domain comprising at least amino acid residues 146-513 of the RSV F protein.

[0048] In some embodiments, the recombinant extracellular domain includes a recombinant F2 domain comprising amino acid residues 26-103 of the RSV F protein and a recombinant F1 domain comprising amino acid residues 145-513 of the RSV F protein.

[0049] In some embodiments, the recombinant extracellular domain includes a recombinant F2 domain comprising amino acid residues 26-103 of the RSV F protein and a recombinant F1 domain comprising amino acid residues 147-513 of the RSV F protein.

[0050] In some embodiments, the recombinant F2 domain and the recombinant F1 domain are connected by a linker sequence of 5-8 amino acid residues consisting of glycine G, proline P, and one or more amino acids selected from serine S, alanine A, glutamic acid E, and lysine K.

[0051] In some embodiments, the linker sequence is a linker sequence of 5-8 amino acid residues consisting of glycine G, proline P and serine S.

[0052] In some embodiments, the linker sequence is a linker sequence of 6 amino acid residues in length consisting of glycine G, proline P and serine S, wherein the linker sequence is GGPGGS.

[0053] In some embodiments, the linker sequence is a linker sequence of 5-8 amino acid residues consisting of glycine G, proline P, serine S and alanine A.

[0054] In some embodiments, the linker sequence is a linker sequence with a length of 5 amino acid residues consisting of glycine G, proline P, serine S and alanine A, wherein the linker sequence is GAPGS.

[0055] In some embodiments, the linker sequence is a linker sequence of 5-8 amino acid residues consisting of glycine G, proline P, alanine A and glutamate E.

[0056] In some embodiments, the linker sequence is a linker sequence of 7 amino acid residues in length consisting of glycine G, proline P, alanine A and glutamic acid E, wherein the linker sequence is GAPEPGE.

[0057] In some embodiments, the linker sequence is a linker sequence of 5-8 amino acid residues consisting of glycine G, proline P, alanine A, glutamic acid E and lysine K.

[0058] In some embodiments, the linker sequence is a linker sequence of 7 amino acid residues in length consisting of glycine G, proline P, alanine A, glutamic acid E and lysine K, wherein the linker sequence is GKPAPGE.

[0059] In some embodiments, the cavity filling mutation is selected from one or more of N67F, S190V, V296F and V495L. In some embodiments, the cavity filling mutation is N67F. In some embodiments, the cavity filling mutation is preferably a combination of N67F, S190V, V296F and V495L.

[0060] In some embodiments, the substitution that increases expression is selected from P102A+I379V+M447V, S46G, L95M, I221M and / or E218A. In some embodiments, the electrostatic mutation is selected from G184N, and in other embodiments, G184N also has the effect of increasing expression.

[0061] In some embodiments, the present invention designs intermolecular disulfide bonds, which refer to disulfide bonds connecting monomers, which can help lock the F protein in the pre-fusion conformation, such as K75C+E218C, K75C+E218C, V144C+I407C or S150C+Y458C, etc. In some embodiments, the present invention designs disulfide bond mutations in the distal region of the fixed membrane, which refers to one of the mutation sites of the disulfide bond mutation at positions 137 to 216 of the F protein, such as I148C+Y286C, S55C+L188C, H159C+I291C or G151C+I288C. In some embodiments, the present invention designs a disulfide bond mutation C-type disulfide bond in the proximal region of the fixed membrane, which means that one of the mutation sites of the disulfide bond mutation is between 460 and 500 of the F protein, such as K399C+S485C, S443C+S466C, T323C+I475C, I332C+P480C or F387C+I492C.

[0062] In some embodiments, the mutation that increases expression level comprises S46G.

[0063] In some embodiments, the mutations that increase expression include G184N, S46G, L95M, and I221M.

[0064] The polypeptide disclosed in the present invention comprises a signal peptide sequence required for expression or a linker sequence connected to a purification tag, and these signal peptide sequences or linker sequences connected to a purification tag can be removed in the final product.

[0065] In some embodiments, the polypeptide is constructed to further comprise a heterologous signal peptide.

[0066] In some embodiments, the heterologous signal peptide is an IgG signal peptide with an amino acid sequence of MGWSCIILFLVATATGVHS.

[0067] In some embodiments, affinity tags for facilitating subsequent purification are also introduced into the polypeptide during vector construction, such as strep tag (amino acid sequence: WSHPQFEK), Monoclonal Flag-Tag (amino acid sequence: DYKDDDDK) and His tag (amino acid sequence: HHHHHHHH). These tag sequences can be removed from the final product.

[0068] The present invention also provides the use of the polypeptide in preparing a vaccine for preventing RSV infection.

[0069] The present invention also provides a vaccine for preventing RSV infection, comprising any one of the above polypeptides; the vaccine provides protection against infection by at least one of RSV A subtype and / or B subtype.

[0070] The present invention discloses a vaccine composition for preventing RSV infection, further comprising an immune adjuvant, wherein the immune adjuvant comprises at least one of aluminum adjuvant, squalene, tocopherol, MPL, LPA, CpG, poly(I:C) and QS-21.

[0071] In some embodiments, the present invention discloses a vaccine for preventing RSV infection, comprising an adjuvant in the form of liposomes, wherein the main components of the adjuvant in the form of liposomes include MPL, QS-21, DOPC and cholesterol. The dosage of the adjuvant can be 0.5 ml per dose, containing 50 μg MPL, 50 μg QS-21, 1 mg DOPC, 0.25 mg cholesterol, 4.835 mg sodium chloride, 0.15 mg anhydrous disodium hydrogen phosphate, 0.54 mg potassium dihydrogen phosphate and water for injection, or it can be one-half, one-quarter or less of the above dosage, for example, the main components include 25 μg MPL, 25 μg QS-21, 0.5 mg DOPC, and 0.125 mg cholesterol.

[0072] RSV virus has two subtypes, A and B, and each subtype has different genotypes. Type A is more common in the population, while type B is more likely to cause lower respiratory tract infections in infants and young children. There is a small amount of antigenic difference between the two subtypes. The technical solution of the present invention also includes providing a respiratory cytological virus antigen composition, characterized in that the respiratory cytological virus antigen composition comprises a first component and a second component, the first component is derived from the F protein of the first strain of respiratory cytological virus, and the second component protein is derived from the F protein of the second strain of respiratory cytological virus, and may also include a third strain or a fourth strain.

[0073] In a specific embodiment, the RSV antigen composition of the present invention includes recombinant respiratory syncytial virus (RSV) polypeptides of subtype A and / or subtype B.

[0074] The invention discloses a recombinant respiratory syncytial virus (RSV) polypeptide, comprising a recombinant extracellular domain of RSV F protein of subtype A or / and subtype B, corresponding to amino acid residues 26-513 of a wild-type RSV F protein sequence shown in SEQ ID NO: 1, and having cysteine ​​mutations K75C+E218C or V144C+I407C compared with the wild-type RSV F protein.

[0075] The invention discloses a recombinant A subtype or / and B subtype respiratory syncytial virus (RSV) polypeptide, which has cysteine ​​mutations I148C+Y286C or S55C+L188C compared with wild-type RSV F protein.

[0076] The invention discloses a recombinant A subtype or / and B subtype respiratory syncytial virus (RSV) polypeptide, which has cysteine ​​mutations K399C+S485C or F387C+I492C compared with wild-type RSV F protein.

[0077] The present invention discloses a polypeptide, wherein the recombinant extracellular domain of subtype A or / and subtype B comprises one of the following combinations of cysteine ​​substitution mutations:

[0078] A. V144C+I407C, K75C+E218C, I148C+Y286C, and F387C+I492C;

[0079] B. V144C+I407C, I148C+Y286C, S55C+L188C, and F387C+I492C;

[0080] C.K75C+E218C, I148C+Y286C, T323C+I475C;

[0081] D.K75C+E218C, I148C+Y286C, F387C+I492C;

[0082] E.K75C+E218C, I148C+Y286C, K399C+S485C;

[0083] F.K75C+E218C, G151C+I288C, K399C+S485C;

[0084] G.K75C+E218C, H159C+I291C, K399C+S485C.

[0085] The polypeptide described in the technical solution of the present invention, wherein the recombinant RSV extracellular domain of subtype A or / and subtype B further comprises a cavity filling mutation, and the cavity mutation site is selected from one, two, three or four of positions 67, 495, 296 and 190 of the amino acid sequence of the wild-type RSV F protein.

[0086] In some embodiments, the preferred cavity-filling mutation is N67F, and in other embodiments, the preferred cavity-filling mutation is N67F+S190V+V296F+V495L.

[0087] The polypeptide described in the technical solution of the present invention, wherein the recombinant extracellular domain of subtype A or / and subtype B further comprises mutations P102A+I379V+M447V, S46G or G184N that increase the expression amount.

[0088] The extracellular domain of the recombinant subtype A or / and subtype B described in the present invention comprises an epitope that only exists in the pre-fusion conformation, and the epitope comprises residues 62-69 and 196-209 of the wild-type RSV F protein sequence shown in SEQ ID NO:1.

[0089] The polypeptide described in the technical solution of the present invention, wherein the recombinant A subtype or / and B subtype extracellular domain includes a recombinant F2 domain comprising at least amino acid residues 26-105 of RSV F protein and a recombinant F1 domain comprising at least amino acid residues 145-513 of RSV F protein.

[0090] In the polypeptide described in the technical solution of the present invention, the recombinant F2 domain is connected to the recombinant F1 domain directly or through a linker.

[0091] In some embodiments, the recombinant F2 domain is connected to the recombinant F1 domain via a linker, which means that the C-terminus of the F2 domain is connected to the N-terminus of the F1 domain via a linker, for example, residues 106-144 of the recombinant extracellular domain of the F protein of subtype A or / and subtype B are replaced by a linker sequence selected from GGPGGS, GAPEPGE or GGSGGSG.

[0092] In some embodiments, the C-terminus of the recombinant polypeptide of subtype A or / and subtype B includes a multimerization domain.

[0093] In some embodiments, the multimerization domain is located at the C-terminus of the recombinant extracellular domain and is directly connected to the C-terminus of the recombinant A subtype or / and B subtype F protein extracellular domain or connected through a linker sequence.

[0094] In some embodiments, optionally, the linker sequence is GGGSSGS, GSGSG, or a 4-10 amino acid sequence consisting of G and S.

[0095] In some embodiments, wherein the multimerization domain is a trimerization domain, the trimerization domain promotes the formation of a trimer of three F1 / F2 heterodimers.

[0096] In some embodiments, the multimerization domain is a domain that can achieve higher polymerization, such as ferritin that can self-assemble to form twenty-tetramers.

[0097] In some embodiments, the multimerization domain is preferably a foldon domain or a ferritin domain.

[0098] In the present application, the antigen dose of the immunogenic composition is 60-120 μg. In a specific embodiment, the antigen is a type A prefusion F protein, or a type B prefusion F protein. In a specific embodiment, the antigen is a subtype A antigen designed by the present invention, or a subtype B antigen, or a subtype of RSV F protein that has been disclosed or unknown. The antigen dose is 7.5 μg, 30 μg, 50 μg, 60 μg, 70 μg, 80 μg, 90 μg, 100 μg, 110 μg, 120 μg, 150 μg, and the preferred antigen dose is 60-120 μg.

[0099] The technical solution of the present invention also includes providing a respiratory syncytial virus antigen composition, wherein the weight ratio of the first component to the second component is (1-4): (1-4), preferably 1: 1. Each component contains 7.5-80 μg of F protein, preferably 30-60 μg. In a suitable embodiment, the antigen comprises a mixture of type A antigen and type B antigen, with 7.5 μg, 30 μg, 50 μg, 60 μg, 70 μg or 80 μg of each subtype of antigen.

[0100] The technical solution of the present invention also includes providing a respiratory syncytial virus immune composition, characterized in that it comprises an adjuvant and an antigen derived from at least one respiratory syncytial virus strain, the antigen comprises a recombinant respiratory syncytial virus (RSV) polypeptide of subtype A and / or subtype B, and the adjuvant is selected from an oil-in-water emulsion adjuvant or a liposome adjuvant.

[0101] The technical solution of the present invention also includes providing that the oil phase of the oil-in-water emulsion is squalene and α-tocopherol, and the emulsifier is Tween 80.

[0102] In a specific embodiment, the oil-in-water emulsion comprises 0.1-25 wt.% of squalene, 0.1-25 wt.% of α-tocopherol and 0.05-6 wt.% of Tween 80.

[0103] In a specific embodiment, each dose of the vaccine comprises 0.5-18 mg of squalene, 0.5-18 mg of tocopherol, and 0.2-6 mg of Tween; preferably, each dose of the vaccine comprises 5-15 mg of squalene, 5-15 mg of tocopherol, and 2-5.5 mg of Tween; in a specific embodiment, more preferably, each dose of the vaccine comprises 9-13 mg of squalene, 9-13 mg of tocopherol, and 4-5 mg of Tween, and in a specific embodiment comprises 10.69 mg of squalene, 11.86 mg of α-tocopherol, and 4.86 mg of Tween 80, and in a specific embodiment comprises 5.35 mg of squalene, 5.93 mg of α-tocopherol, 2.43 mg of Tween 80,

[0104] In a specific embodiment, the standard dose emulsion for one person comprises 10.69 mg of squalene, 11.86 mg of α-tocopherol, 4.86 mg of Tween 80, 3.53 mg of sodium chloride, 0.09 mg of potassium chloride, 0.51 mg of disodium hydrogen phosphate, and 0.09 mg of potassium dihydrogen phosphate. The emulsion dose contained in each dose of vaccine is 1 / 2 or 1 / 4 of the standard dose emulsion for one person.

[0105] The present invention also provides a method for preparing the polypeptide, comprising the following steps:

[0106] S1, synthesizing the DNA sequence corresponding to the polypeptide and cloning it into a plasmid vector;

[0107] S2, transfecting host cells with the recombinant plasmid vector and expressing the recombinant plasmid vector, wherein the host cells are eukaryotic cells;

[0108] S3. Purify the culture product to obtain the polypeptide.

[0109] In some embodiments, the vaccine of the present invention generally also includes a pharmaceutically acceptable carrier and / or excipient such as a buffer. Pharmaceutically acceptable carriers and excipients are well known and can be selected by those skilled in the art. Optionally, a pharmaceutically acceptable carrier or excipient also contains at least one component that stabilizes solubility and / or stability. Examples of solubilizers / stabilizers include detergents, such as laurel sarcosine and / or tween. Other examples of solubilizers / stabilizers include arginine, sucrose, trehalose, etc. Therefore, those skilled in the art can select suitable excipients and carriers to produce formulations suitable for administration to a subject by a selected route of use. Suitable excipients include, but are not limited to, glycerol, polyethylene glycol, KCl, calcium ions, magnesium ions, manganese ions, zinc ions, and other divalent cation-related salts, etc.

[0110] Generally, an adjuvant should be selected to enhance a Th1 biased immune response in a subject or subject population to which the vaccine is administered and to be safe and effective in the subject or subject population.

[0111] The present invention also provides a method for preparing the above-mentioned vaccine for preventing RSV infection, which comprises:

[0112] S1. culturing mammalian host cells to express the polypeptide;

[0113] S2. Purifying the polypeptide expressed in step (1);

[0114] S3. Fully mix the purified polypeptide and immune adjuvant according to the proportion.

[0115] In some embodiments, additional steps such as gene synthesis, construction of expression vectors, and freeze-drying of purified proteins are also included. The expressed fusion polypeptide can be recovered and purified from the recombinant cell culture by any one or more of many methods known in the art, including ammonium sulfate or ethanol precipitation, acid extraction, filtration, ultrafiltration, centrifugation, anion / cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxyapatite chromatography, and lectin chromatography. Finally, high performance liquid chromatography HPLC can be used in the final purification step.

[0116] Compared with the prior art, the present invention has the following beneficial effects:

[0117] The present invention obtains an RSV polypeptide with high expression level and immunogenicity that can retain specific epitopes for Pre-F by performing stabilization modification and multimerization (such as trimerization) designs on the wild-type RSV F protein, while maintaining a stable pre-fusion conformation and ensuring that it can induce effective neutralizing antibody responses and binding antibody responses to respiratory syncytial virus. BRIEF DESCRIPTION OF THE DRAWINGS

[0118] The following drawings are only intended to illustrate and explain the present invention, and are not intended to limit the scope of the present invention.

[0119] in:

[0120] Figure 1 (A): Collected effluent peaks and chromatogram of DS-Cav1A;

[0121] Figure 1 (B): Collected effluent peaks and chromatogram of DS-Cav1B;

[0122] Figure 2 (A): Electrophoresis results of DS-Cav1A;

[0123] Figure 2(B): Electrophoresis results of DS-Cav1B;

[0124] Figure 3 :The neutralizing antibody titers against RSV A2 induced by RSV vaccine antigen F196 and different adjuvants in BALB / c mice;

[0125] Figure 4 : Cross-protective neutralizing antibody titers of RSV vaccine against type B virus in mouse (BALB / c) model;

[0126] Figure 5 :Neutralizing antibody titer against RSV type A virus after RSV vaccine immunization of large-eared white rabbits;

[0127] Figure 6 :The cross-protective neutralizing antibody titer against type B virus after immunizing large-eared white rabbits with 120 μg of RSV vaccine antigen;

[0128] Figure 7 : Neutralizing antibody titers of type B virus in mice (BALB / c) immunized with RSV bivalent vaccine;

[0129] Figure 8 : In the pre-fusion conformation of F49 (K75C + E218C), two amino acids are separated

[0130] Fig. 9 : The N-cysteine-substituted RSV F protein has substitution sites separated by less than

[0131] Fig.10 : The substitution sites in the prefusion conformation of the C-class cysteine-substituted RSV F protein are less than DETAILED DESCRIPTION

[0132] The present invention will be further described below by non-limiting examples, and it is well known to those skilled in the art that many modifications may be made to the present invention without departing from the spirit of the present invention, and such modifications also fall within the scope of the present invention. The following examples are only intended to illustrate the present invention and should not be considered to limit the scope of the present invention, because the embodiments are necessarily diverse. The terms used in this specification are only intended to illustrate specific embodiments, and not as a limitation, and the scope of the present invention is defined in the appended claims.

[0133] Unless otherwise specified, all technical and scientific terms used in this specification have the same meaning as those generally understood by those skilled in the art to which this invention belongs. The preferred methods and materials of the present invention are described below, but any methods and materials similar or equivalent to those described in this specification can be used to implement or test the present invention. The following experimental methods are conventional methods or methods described in product specifications unless otherwise specified, and the experimental materials used can be easily obtained from commercial companies unless otherwise specified.

[0134] Definition of terms

[0135] In this application, the term "DS-Cav1" refers to the PreF design concept of CN105473604B, including a pre-F trimer stabilized by a disulfide bond between residues 155 and 290 ("DS"), cavity-filling mutations S190F and V207L ​​("Cav1"), and an additional C-terminal fibritin (i.e., foldon) trimerization domain, and the specific sequence is given in the examples.

[0136] In the present application, the term "D25" refers to the antibody described in CN101778866B, and its specific amino acid sequence refers to SEQ ID NO: 1-8 in the specification.

[0137] In the present application, the term "101F" refers to the antibody described in US20060159695A1, and the nucleotide and amino acid sequences of the heavy and light chains thereof refer to SEQ ID NOs: 3-6 in the specification.

[0138] In the present application, the term "AM14" refers to the antibody described in CN101778866B, and the specific sequence refers to the amino acid sequence of AM14 in Example 4 of the patent specification.

[0139] In the present application, the term "Mota" or "Motavizumab" refers to the antibody described in WO2007002543A2, and its specific sequence refers to the amino acid sequence SEQ ID NO:48 and SEQ ID NO:11 of the A4B4L1FR-S28R antibody in the patent specification.

[0140] In the present application, each mutant of the present invention is designed and prepared based on the wild-type (abbreviated as WT) RSV F protein amino acid sequence described in SEQ ID NO: 1. The F protein polypeptide of the RSV can be selected from any F protein of RSV A strain, RSV B strain, HRSV A strain, HRSV B strain, BRSV strain or avian RSV strain, or a variant thereof. In certain embodiments, the wild-type F protein polypeptide is an F protein represented by SEQ ID NO: 1. In order to assist in understanding the present disclosure, all amino acid residue positions, regardless of the strain, are given for (i.e., the position of the amino acid residue is relative to) the amino acid position of the exemplary F protein. The corresponding amino acid positions of the F proteins from other RSV strains can be easily determined by a person of ordinary skill in the art by comparing the amino acid sequence of the selected RSV strain with the exemplary sequence using a conveniently available and well-known alignment algorithm (such as BLAST, for example, using default parameters).

[0141] The F2 polypeptide comprises at least a portion or all of amino acid residues 26-106 of SEQ ID NO: 1, such as 26-100, 26-102, 26-104, 26-105 or 26-106, except for the mutations introduced as described. The F1 polypeptide comprises at least a portion or all of amino acid residues 136-513 of SEQ ID NO: 1, such as 136-500, 140-500, 136-510, 136-512 or 136-513, except for the mutations introduced as described.

[0142] The C-terminus of the F2 domain can be the 100th, 101st, 102nd, 103rd, 104th, 105th or 106th position in the sequence of SEQ ID NO:1. The C-terminus of the F2 domain is directly or through a linker connected to the N-terminus of the F1 domain. The N-terminus of the F1 domain can be the 136th, 137th, 138th, 140th, 141st, 142nd, 143rd, 144th, 145th or 146th position in SEQ ID NO:1. The C-terminus of the F1 domain can be the 499th, 500th, 502nd, 503rd, 504th, 505th, 506th, 508th, 510th or 513th position in SEQ ID NO:1. The C-terminus of the F1 domain can be directly or through a linker connected to a trimerization domain or a multimerization domain.

[0143] The term "N-type cysteine ​​substitution" refers to a pair of cysteine ​​substitutions in which one mutation site is between positions 137 and 216 of the F protein. Preferably, the distance between the two mutation sites is less than The difference between the distance before and after fusion is less than In the specification, Class N and Class RR1 have the same meaning and can be interchanged.

[0144] The term "Class C cysteine ​​substitution" mutation refers to a pair of cysteine ​​substitutions in which one mutation site is between positions 460 and 500 of the F protein. Preferably, the distance between the two mutation sites is less than The difference between the distance before and after fusion is less than In the specification, Class C and Class RR2 have the same meaning and can be interchanged.

[0145] The terms "multimerization domain" and "multimerization" refer to a polypeptide or a domain of a polypeptide that forms dimers, trimers, tetramers, pentamers, hexamers and / or twenty-tetramers with other more multimerization domains. Trimerization domains are for example foldon, GCN4 or MTQ.

[0146] In the present application, the term "GCN4" refers to the yeast transcription activator GCN4, which is a protein that binds to DNA through a leucine zipper (bZIP) structure. The sequence of GCN4 in the present application is IKRMKQIEDKIEEIESKQKKIENEIARIKKIK.

[0147] In the present application, the term "MTQ" is a trimerization motif, and the sequence of MTQ in the present application is IKEEIAKIKEEQAKIKEKIAEIEKRIAEIEKRIAGGCC.

[0148] Example 1. Plasmid construction, transformation and preparation

[0149] The amino acid sequences of each construct were designed according to Table 1, including the wild-type (WT) sequence, the ferritin sequence, the Fecto-Ferritin group sequence (extracellular domain of F protein + ferritin sequence) and the DS-Cav1B group sequence. In addition, the DS-Cav1A group was designed by performing disulfide bond mutations S155C and S290C, and cavity filling mutations S190F and V207L ​​on the WT sequence. The sequence of the DS-Cav1A group was further subjected to P102A, I379V and M447V amino acid substitution mutations to obtain the DS-Cav1B group sequence.

[0150] The amino acid sequence is codon optimized according to the host CHO cells to determine the nucleic acid sequence for gene synthesis.

[0151] Table 1: Construct amino acid sequence design

[0152] name Amino acid sequence SEQ ID NO: WT 1 Ferritin 2 F ecto-Ferritin 3 Control DS-Cav1B 4 F49(K75C+E218C) 5 F50(V144C+I407C) 6 F30(S55C+L188C) 7 F44(F387C+I492C) 8 F45(K399C+S485C) 9 F231(V144C+I407C, I148C+Y286C, F387C+I492C) 10 F233(K75C+E218C, I148C+Y286C, K399C+S485C) 11 F188 12 F179 13 F194A subtype 14 F196A subtype 15 F194B subtype 16 F196B subtype 17

[0153] The synthesized target gene was inserted into the eukaryotic plasmid pCHO3.1 vector for transfection and expression. Each constructed recombinant plasmid was transformed into Escherichia coli DH5α competent cells, and the glycerol bacteria into which the plasmid containing the target gene was transferred were transferred to 150mL LB liquid medium (final Amp concentration was 100μg / ml), and cultured overnight in a shaking incubator at 37°C and 2000rpm. The plasmid was extracted using an endotoxin-free plasmid extraction kit, and the plasmid concentration of the extract was measured and enzyme digestion was performed for identification. The specific reaction system is shown in Table 2.

[0154] Table 2: Enzyme digestion reaction system

[0155]

[0156] After plasmid amplification, the concentration was measured, and each plasmid was able to obtain a relatively high amplification concentration, about 600-900 μg / ml, and the total amount was about 1.0 μg. The results of enzyme cutting were detected by 1% agarose gel electrophoresis, and clear bands were visible at the corresponding size. All plasmids were sequenced, and after identification, the target gene sequences of all plasmids were completely correct. The recombinant plasmid vector carrying the target gene has been successfully transferred into the host cell and has been successfully amplified.

[0157] A plasmid having the following intermolecular cysteine ​​substitution mutation was also constructed with reference to the above. After plasmid amplification, the amplification concentration of the plasmid having the intermolecular cysteine ​​substitution mutation (also called "intermolecular disulfide bond mutation") was examined. The results are shown in the following table.

[0158] Table 3: Plasmid concentration determination results

[0159]

[0160]

[0161] The results showed that the plasmids with higher amplification concentrations were mainly pCHO3.1-F46, pCHO3.1-F47, pCHO3.1-F48, pCHO3.1-F49 and pCHO3.1-F50.

[0162] Example 2. Protein expression

[0163] The obtained plasmid was introduced into CHO cells by transient transfection, and the protein supernatant was collected after culture.

[0164] ExpiCHO-S cells (Thermo) were cultured in EmCD CHO-S203 (Eminence / L20301) medium supplemented with 6 mM L-glutamine (sigma / G5146). One day in advance, 96-well plates were plated at a density of 0.25E5 cells / well (supplemented with 10% FBS) and cultured statically in an incubator at 37°C and 8% CO2. On the day of transfection, the 96-well plates with cells were replaced with fresh EmCD CHO-S203 medium containing L-glutamine. The transfection incubation system was prepared with EmCD CHO-S203 medium containing L-glutamine (volume was 50% of the transfection volume), wherein the DNA dosage was 1 μg / ml, and the ratio of transfection reagent PEI (Polysciences / 24765-1) to DNA was 3. PEI and DNA were mixed and incubated for 5 minutes and then added to a 96-well plate with cells. The culture was incubated in an incubator at 37°C and 8% CO2. After 24 hours of transfection, the temperature was lowered to 32°C for culture, and Advanced Feed1 (sigma / 24368-1L) was added as feed at a volume ratio of 5%. The culture was stopped on the 7th day after transfection and the supernatant was collected.

[0165] Example 3. Evaluation experiment on increasing protein expression

[0166] The DS-Cav1A protein supernatant sample and the DS-Cav1B protein supernatant sample stored at 4°C were used as two parallel samples for molecular sieve chromatography. The molecular sieve chromatography column had a height-to-diameter ratio of 40:1, and the filler was Superdex200; the mobile phase was 2.5% mercaptoethanol, 20mmol / L pH8.0 Tris-HCl; the flow rate was 50cm / hr; the sample loading amount was less than 5% (v / v) of the column bed volume, and the effluent peaks were collected step by step (see the attached chromatogram for the attached Figure 1(A) , 1(B) , electrophoresis results are attached Figure 2(A) , 2(B) ).

[0167] The applicant unexpectedly found that, in comparison, the three natural substitutions P102A, I379V and M447V in DS-Cav1B can greatly increase the protein expression. The DS-Cav1 used in the control experiments in the following examples refers to the optimized DS-Cav1B.

[0168] Example 4. Design of a single mutation scheme for F protein

[0169] Each mutant of the present invention is designed and prepared based on the wild-type (abbreviated as WT) RSV F protein amino acid sequence described in SEQ ID NO:1. This embodiment illustrates the design of various F protein single mutants, which are provided in the form of trimers, including foldon domains and introduced amino acid mutations, such as cavity filling mutations. These F protein single mutants include IgG signal peptide (MGWSCIILFLVATATGVHS), two separate polypeptide chains. One of the polypeptide chains, the F2 polypeptide includes amino acids 26-106 of SEQ ID NO:1, except for the mutations introduced as described. Another polypeptide chain includes the F1 polypeptide (residues 136-513) connected to the N-terminus of the foldon domain, and except for the mutations introduced as described, their commonly introduced modifications also include del_P27 replaced with ARGSGSG, R106Q and F137S. It also includes purification tag His-Tag (HHHHHHHH), affinity tag Monoclonal Flag-Tag (DYKDDDDK) and linker sequence (e.g. GSGSG). The signal peptide (residues 1-25) and pep27 (residues 110-136) of SEQ ID NO: 1 are cleaved from the F0 precursor during the expression process.

[0170] The amino acid sequences of each RSV F protein mutant and control group protein were designed according to the table below. The amino acid sequence was codon optimized according to the host CHO cells to determine the nucleic acid sequence and perform gene synthesis.

[0171] Table 4: Mutants containing only cavity-filling mutations

[0172]

[0173]

[0174] In addition, a single mutant of the F protein containing only the linker sequence shown in the table below was designed and constructed by replacing residues 104-144 in the template amino acid sequence with the linker sequence. The amino acid sequence was codon-optimized according to the host CHO cells to determine the nucleic acid sequence and perform gene synthesis.

[0175] Template amino acid sequence:

[0176] MELLILKANAITTILTAVTFCFASG QNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQSTPATNNRARRELPRFMNYTLNNAKKTVTTLSKKRKRRFLGFLLGVGSA IASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQLLPIVNKQSCSISNIATVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITND QKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKY DCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELL SAIG GYIPEAPRDGQAYVRKDGEWVLLSTFL GG LVPRGSHHHHHHSAWSHPQFEK.

[0177] Table 5: Linker sequence design

[0178] Serial number Linker amino acid sequence 1 GGPGGS 2 GGPGPGSE 3 GAPGS 4 GAPEPGE 5 GAPEPAPGE 6 GAPAPAPKPGE 7 GKPAPGE

[0179] Plasmid transformation, preparation and enzyme digestion identification were performed according to the method of Example 1. The concentration was measured after plasmid amplification, and each plasmid could obtain a high amplification concentration. All plasmids were sequenced and identified to have the correct target gene sequence. The recombinant plasmid vector carrying the target gene has been successfully transferred into the host cell and has been successfully amplified.

[0180] Example 5. Screening of intermolecular disulfide bond mutation schemes

[0181] The obtained plasmid was introduced into CHO cells by transient transfection, and the protein supernatant was collected after culture. The protein supernatant sample was diluted with PBS to 5 ng / μL with coated antibody D25 or coated antibody Motavizumab (Mota for short), and 200 μL was added to each well of the 96-well plate and incubated overnight at 4°C. Wash once with PBST. Block the ELISA detection plate with 250 μL 2% BSA / PBS, block at room temperature for 1 hour, and wash once with PBST. Add 200 μL of protein supernatant to each well and incubate at room temperature for 1 hour. Wash 3 times with PBST. Dilute the HRP-labeled antibody to the appropriate dilution (D25-1:8000, Mota-1:16000) in 0.2% BSA / PBS, add 200 μL to each well, and incubate at room temperature for 1 hour. Wash 4 times with PBST. Add 100 μL of substrate solution (TMB two-component solution A:B = 1:1 mixture), react at room temperature for 15-20 min, add 100 μL of stop solution, and read the OD value.

[0182] Table 6: Binding of intermolecular disulfide bond mutants to D25 and Mota

[0183]

[0184]

[0185] Selection of intermolecular disulfide bond design scheme 1) refers to the OD value of D25 antibody, 2) also refers to the OD value of Mota antibody, F50, F51, F54, F56, and F49 are the mutants with the highest expression of different intermolecular disulfide bond mutation designs. Further combined with the measurement results of plasmid concentration in Table 3 in Example 1, the preferred mutation designs include F49, F54, F50 and F56.

[0186] Example 6. Screening of N-type cysteine ​​substitution mutation schemes

[0187] Regarding the screening of N-type cysteine ​​substitution mutation schemes, the following single mutant plasmids were introduced into CHO cells by transient transfection. After culture, the protein supernatant was collected and placed at 4°C for 7 days before detection.

[0188] Use PBS to dilute the coated antibody D25 or the coated antibody Motavizumab (Mota for short) to 5ng / μL, add 200μL to each well of the 96-well plate, and incubate overnight at 4°C. Wash once with PBST. Block the ELISA test plate with 250μL 2% BSA / PBS, block at room temperature for 1 hour, and wash once with PBST. Add 200μL protein supernatant to each well and incubate at room temperature for 1h. Wash 3 times with PBST. Dilute the HRP-labeled antibody to the appropriate dilution (D25-1:8000, Mota-1:16000) in 0.2% BSA / PBS, add 200μL to each well, and incubate at room temperature for 1 hour. Wash 4 times with PBST. Add 100μL substrate solution (TMB two-component solution A:B=1:1 mixture), react at room temperature for 15-20min, add 100μL stop solution, read the OD value for different antibodies, and calculate the sample concentration according to the regression analysis equation. Calculate the activity concentration ratio of D25 and Mota after the protein was placed at 4°C for 7 days.

[0189] Table 7: OD values ​​of N-type cysteine-substituted mutants and the ratio of D25 to Mota concentration after 7 days of placement

[0190]

[0191]

[0192] The selection of the disulfide bond design scheme for RR1 1) refers to the OD value of the D25 antibody, 2) also refers to the OD value of the Mota antibody. F34, F30, F25, and F26 are the mutants with the highest expression designed by different intermolecular disulfide bond mutations, and have higher expression levels and antibody binding activity than the wild-type WT.

[0193] The PreF conformation ratio (concentration ratio in the last column) was further detected after the protein samples were placed at 4°C for 7 days. The results showed that the F27, F25, F26 and F30 protein supernatants could still detect a higher PreF conformation ratio after being placed at 4°C for 7 days, indicating that their N-type cysteine ​​substitution mutation schemes are more conducive to maintaining the pre-fusion conformation of the F protein in a general vaccine storage environment. Therefore, the preferred N-type cysteine ​​substitution mutations are F30, F27, F25 and F26.

[0194] Example 7. Screening of Class C Cysteine ​​Substitution Mutation Schemes

[0195] Regarding the screening of C-type cysteine ​​substitution mutation schemes, the following single mutant plasmids were introduced into CHO cells by transient transfection, and the protein supernatant was collected for detection after culture.

[0196] Use PBS to dilute the coated antibody Motavizumab (Mota for short) to 5ng / μL, add 200μL to each well of the 96-well plate, and incubate overnight at 4℃. Wash once with PBST. Block the ELISA test plate with 250μL 2% BSA / PBS, block for 1 hour at room temperature, and wash once with PBST. Add 200μL protein supernatant to each well and incubate for 1h at room temperature. Wash 3 times with PBST. Dilute the HRP-labeled antibody to the appropriate dilution (Mota-1:16000) in 0.2% BSA / PBS, add 200μL to each well, and incubate for 1 hour at room temperature. Wash 4 times with PBST. Add 100μL substrate solution (TMB two-component solution A:B=1:1 mixture), react at room temperature for 15-20min, add 100μL stop solution, and read the OD value.

[0197] Table 8: OD values ​​of mutants with cysteine ​​substitution in class C

[0198]

[0199]

[0200] Selection of the disulfide bond design scheme for RR2 1) refers to the OD value of D25 antibody, 2) also refers to the OD value of Mota antibody. F42, F44, F41 and F45 are the mutants with the highest expression of RR2 disulfide bond mutation design, with higher expression and antibody binding activity compared to wild-type WT. Therefore, the preferred RR2 cysteine ​​substitution mutation schemes are I332C+S485C, F387C+I492C, I332C+P480C and K399C+S485C.

[0201] Example 8. Screening of different types of disulfide bond mutation designs

[0202] RSV F mutant plasmids were designed according to the table below, including introducing the constructed plasmids of different types of cysteine ​​mutations into CHO cells by transient transfection, collecting the protein supernatant after culture, and dividing it into two samples, which were stored at 4°C and stored after heating at 60°C for 1 hour. The following tests were performed.

[0203] Use PBS to dilute the coated antibody Motavizumab (Mota for short) and D25 to 5ng / μL, add 200μL to each well of the 96-well plate, and incubate overnight at 4℃. Wash once with PBST. Block the ELISA detection plate with 250μL 2% BSA / PBS, block at room temperature for 1 hour, and wash once with PBST. Add 200μL protein supernatant to each well and incubate at room temperature for 1h. Wash 3 times with PBST. Dilute the HRP-labeled antibody to the appropriate dilution (Mota-1:16000) in 0.2% BSA / PBS, add 200μL to each well, and incubate at room temperature for 1 hour. Wash 4 times with PBST. Add 100μL substrate solution (TMB two-component solution A:B=1:1 mixture), react at room temperature for 15-20min, add 100μL stop solution, read the OD value, and calculate the concentration ratio of 60℃ / 4℃.

[0204] Table 9: Concentration ratio of mutants with different types of cysteine ​​mutations

[0205]

[0206]

[0207] The DS mutation in DS-Cav1 refers to S155C+S290C, which belongs to the RR1 mutation. The results showed that compared with the DS mutation in the design of DS-Cav1, the thermal stability of F44 and F45 of the RR2 disulfide bond mutations and F50 and F49 of the Inter disulfide bond mutations was higher, which means that the proteins with RR2 or Inter mutations have a stronger ability to maintain their three-dimensional structure and function under high temperature conditions, and the thermal stability of F49 is even higher than that of DS-Cav1, which includes the combination of disulfide bond mutations S155C+S290C and cavity mutations S190F and V207L, indicating that the mutation design of F49 has stronger intermolecular forces.

[0208] The combined mutation of disulfide bonds in F232 has a thermal stability comparable to that of DS-Cav1, while the combined mutation of F233 has a thermal stability superior to that of DS-Cav1 and has stronger intermolecular forces.

[0209] Example 9. Evaluation of the thermal stability of the conformation of the intermolecular disulfide bond K75C+E218C

[0210] Referring to the intermolecular disulfide bond design scheme, we further designed a polypeptide that introduced combinatorial mutations in RSV F ecto (extracellular domain), focusing on the combinatorial screening of intermolecular disulfide bond mutations.

[0211] The expressed candidate protein was prepared in large quantities and purified using a two-step purification method of nickel column affinity chromatography and molecular sieve chromatography. The protein concentration was diluted to the detection concentration, and the Pre-F prefusion conformation-specific monoclonal antibody D25 was used to identify the prefusion conformational stability of the purified protein after incubation for 1 hour.

[0212] In conjunction with the design of a single mutation of the protein, we first further investigated the effect of the intermolecular disulfide bond mutation K75C+E218C on the thermal stability of the F protein before fusion. The conformational thermal stability reference value is characterized by the sum of the D25 concentration ratios of different batches of proteins after one hour of heat treatment and at 4°C. The conformational thermal stability reference value in the table below is mainly the sum of the D25 concentration ratios of two batches and three times, including the D25 concentration ratio of the 0512 batch of proteins after one hour of 60°C treatment and at 4°C, the D25 concentration ratio of the 0512 batch of proteins after one hour of 70°C treatment and at 4°C, and the D25 concentration ratio of the 0509 batch of proteins after one hour of 70°C treatment and at 4°C. The results are shown in the table below.

[0213] Table 10: Combinatorial screening of inter disulfide bond mutations and conformational thermal stability evaluation

[0214]

[0215] The results of thermal stability of the control group without intermolecular disulfide bonds are shown in the following table.

[0216] Table 11: Control combination screening and conformational thermal stability evaluation

[0217]

[0218]

[0219] In terms of the thermal stability of the PreF conformation, the protein samples were incubated at 60°C or 70°C for 1 hour. Compared with the F protein without the intermolecular disulfide bond design, the pre-fusion conformation of the F protein with the K75C+E218C mutation design and other combinations of the inter disulfide bond design was relatively stable. However, without the intermolecular disulfide bond K75C+E218C design, the stability of the protein would be significantly reduced.

[0220] Example 10. Evaluation of the thermal stability of PreF conformations of combined mutants with a granulation domain

[0221] Based on the preferred inter disulfide bond mutations, N-type disulfide bond mutations and C-type disulfide bond mutations, a protein expressing a multimerization domain (ferritin, a particle domain) at the C-terminus of the polypeptide was prepared in large quantities according to the following table, and purified using a two-step purification method of nickel column affinity chromatography and molecular sieve chromatography. The purified protein was placed at 4°C and incubated at 60°C for 1 hour, and then the protein concentration was diluted to the detection concentration, and the Pre-F pre-fusion conformation-specific monoclonal antibody D25 was used to identify the protein and investigate the thermal stability of the pre-fusion conformation of the protein.

[0222] Table 12: Design of combinatorial mutants with granulation domains

[0223]

[0224] Table 13: Evaluation of thermal stability of pre-fusion conformations of combined mutants with granulation domains

[0225]

[0226] The results showed that both the purified protein placed in a 4°C environment and the protein incubated at 60°C for 1h could bind to the prefusion conformation-specific monoclonal antibody D25, and could successfully retain the prefusion conformation of the F protein. Although the prefusion conformation detected in some combined mutants decreased to varying degrees after heat treatment at 60°C, it was observed that the prefusion conformation detected in F189, F192, and F194 was almost unchanged, and the D25 ratios (60°C / 4°C) were 1.07, 1.07, and 0.91, respectively. Considering the measured D25 concentrations, F189, F192, and F194 were preferred.

[0227] Example 11. Immunological evaluation

[0228] Female BALB / C mice aged 6-8 weeks were selected for immunization and randomly divided into groups of 6 mice each. The mice were immunized with the vaccine at two points by intramuscular injection on days 0 and 21, 50 μL each in the left and right legs. The immunogens included candidate antigens F188 (SEQ ID NO: 12), F179 (SEQ ID NO: 13), F194 (SEQ ID NO: 14), and F196 (SEQ ID NO: 15) and a positive control group of DS-Cav1 (SEQID NO: 4); and a negative control group of PBS. The antigen dose was 12 μg / mouse, and the AS01 adjuvant dose was 1 / 20 HD per mouse.

[0229] AS01 adjuvant is a liposome adjuvant, the main components of which include MPL, QS-21, DOPC and cholesterol. 1HDAS01 adjuvant is 0.5ml, containing 50μg MPL, 50μg QS-21, 1mg DOPC, 0.25mg cholesterol, 4.835mg sodium chloride, 0.15mg anhydrous disodium hydrogen phosphate, 0.54mg potassium dihydrogen phosphate and water for injection. Serum was collected on the 20th and 35th days, respectively, and the collected serum was stored at -20°C for subsequent detection of binding antibodies and neutralizing antibodies.

[0230] Combined antibody detection:

[0231] (1) Dilute the serum sample to be tested with sample diluent;

[0232] (2) The positive control serum was diluted 1:10,000 with sample diluent, and the negative control serum was diluted 1:200 with sample diluent;

[0233] (3) Sample loading: Add the serially diluted serum samples to be tested, negative control serum, positive control serum and blank control solution (sample diluent is used as blank control) to the pre-F ELISA plate at 100 μl / well, with the serum samples to be tested added to 1 well and the control solution added to 2 wells; add the sample diluent to the IgG-UNLB ELISA plate at 100 μl / well;

[0234] (4) Incubation: Incubate the ELISA plate at 37°C for 30 min and wash the plate five times with washing buffer in an automatic plate washer;

[0235] (5) Add enzyme: Add 100 μl / well of enzyme-labeled secondary antibody (HRP Goat Anti-Mouse IgG (H+L), ABclonal) to the ELISA plate, incubate at 37°C for 30 min, and wash the plate five times with washing buffer in an automatic plate washer;

[0236] (6) Color development: Mix equal volumes of color development solution A and color development solution B (Feijing Biotechnology), add 100 μl / well to the ELISA plate, and incubate at room temperature in the dark for 15 min;

[0237] (7) Termination: Add 50 μl / well of stop solution to terminate the reaction;

[0238] (8) Plate reading: The absorbance was measured at a wavelength of 450 nm (reference wavelength was 620 nm) using an ELISA reader. The results are shown in the following table.

[0239] Table 14: Pre-F specific IgG content (five-week serum)

[0240]

[0241] After booster immunization, the Pre-F IgG GMC (geometric mean concentration) detected in the serum of each group of mice at 5 weeks increased significantly to varying degrees compared with that at 3 weeks. The pre-F IgG GMC (geometric mean concentration) of F196 and F179 was higher than that of the positive control DS-Cav1 (referring to the PreF design concept of CN105473604B, including the pre-F trimer stabilized by the disulfide bond between residues 155 and 290 ("DS"), the cavity filling mutations S190F and V207L ​​("Cav1") and the additional C-terminal foldon trimerization domain).

[0242] Neutralizing antibody detection:

[0243] Neutralizing antibodies are indicators of immune effects that can specifically recognize antigen neutralizing sites on the surface of the virus, prevent the virus from invading cells and multiplying, and protect the body from harm. They have real antiviral effects. Zhongke Guobang was commissioned to use the RSVA2 strain to perform neutralizing antibody testing through the fluorescent spot reduction neutralization test (FRNT method). The specific steps are:

[0244] (1) Sample preparation: serum stored at -20°C was thawed at room temperature, heat inactivated at 56°C for 30 min, taken out after 30 min and cooled to room temperature, and then the six serum samples in each group were fully mixed to obtain mixed serum samples for each group.

[0245] (2) Sample loading and dilution: 40-fold initial dilution, followed by 4-fold dilution, for 6 dilutions. Take a 96-well plate, use the second column as the cell control (CC), and the third column as the virus control (VC). Add the 20-fold diluted sample to wells B4-B11, use a multichannel pipette to gently mix the liquid in wells B4-B11, and then perform a 4-fold dilution until wells G4-G11. Take the positive reference and negative reference for loading and dilution.

[0246] (3) Virus dilution: Dilute the virus to 800-1200 FFU / well on ice and add to each well except the cell control.

[0247] (4) Place the above 96-well plate in a 37°C, 5% CO2 incubator and incubate for 1 hour.

[0248] (5) HEp-2 cells were digested and counted and adjusted to 2.0×10 using complete culture medium. 5 pcs / mL, 100 μL / well was added into a 96-well plate.

[0249] (6) The cells were cultured in a 37° C., 5% CO 2 incubator. After 24-28 hours, GFP fluorescent spots were counted using a cell imaging multifunctional microplate detection system and the results were recorded.

[0250] (7) 50% neutralizing antibody inhibition rate (ND 50 ) calculation: the fluorescence spot value read by the instrument is input into the data analysis template, and the 50% neutralizing antibody inhibition rate (ND 50 ).

[0251] In addition, Beijing Yunling Metrology and Testing Co., Ltd. was commissioned to conduct auxiliary testing, mainly using the RSV long strain through the CPENT method using the luciferase reporter gene and chemiluminescence detection. The test results are shown in the following table.

[0252] Table 15: Neutralizing antibody titers

[0253]

[0254] It can be seen from the above experiments that the antigen and vaccine composition provided by the present invention can induce the production of high-titer neutralizing antibodies against RSV virus, and the neutralization effect on RSV is better than that of the positive control groups. This also suggests that the vaccine will provide better protective effects when the virus invades, which is of great significance to the research and development of RSV candidate vaccines.

[0255] Example 12. Immunological evaluation of different adjuvants

[0256] Based on the mouse (BALB / c) model, the RSV vaccine antigen (SEQ ID NO: 15) dose and different adjuvants were screened. The detection method was FRNT (type A). Blood was collected and tested 14 days after the last immunization. The immunization method was intramuscular injection of 0.1 ml per mouse. The evaluation results are shown in the attached Figure 3 (Neutralizing antibody titers of BALB / c mice immunized with RSV vaccine antigen and different adjuvants). The neutralizing antibody titers of the AS03 adjuvant group were higher than those of the half-dose AS01 adjuvant group, indicating that the AS03 adjuvant group was superior to the half-dose adjuvant group in the liposome form. The human dose of the oil-in-water emulsion can be 5-15 mg of squalene, 5-15 mg of tocopherol, and 2-5.5 mg of Tween. The preferred dose of the antigen is 120 μg per person.

[0257] Table 16: Mouse testing groups of different doses and different adjuvants of F196

[0258]

[0259] Example 13. Immunological evaluation of cross protection of candidate antigens

[0260] Screening study of RSV vaccine antigen doses of F194 (SEQ ID NO: 14) and F196 (SEQ ID NO: 15) and different adjuvants in a mouse (BALB / c) model. The detection method was FRNT (the detection strain was subtype B 18537). Blood was collected and tested 14 days after the last immunization. The evaluation results are shown in the attached Figure 4 (Neutralizing antibody titer of cross-protection of mouse (BALB / c) RSV vaccine antigen against type B virus). The neutralizing antibody titer of AS03 adjuvant group was higher than that of half-dose AS01 adjuvant group, indicating that AS03 adjuvant group was superior to half-dose adjuvant group in liposome form. The human dose of oil-in-water emulsion can be squalene 5-15 mg, tocopherol 5-15 mg, Tween 2-5.5 mg. The positive control group was GSK's marketed vaccine AREXVY (antigen batch number 4JY53).

[0261] Table 17: Detection grouping of RSV antigens against recombinant RSV B-GFP virus

[0262]

[0263]

[0264] The B subtype used for RSV virus detection is 18573, and the test results are attached. Figure 4 This shows that type A antigens F194 and F196 have cross-protective immune effects, just like the type A RSV recombinant vaccine marketed by GSK.

[0265] Example 14. Immunological evaluation of different antigen doses

[0266] In the study of RSV vaccine immunogenicity of F194 (SEQ ID NO: 14) and F196 (SEQ ID NO: 15) using large-eared white rabbits as models, the experimental animals were immunized with two injections at an interval of 3 weeks. The dose of the immunizing antigen was 60 μg or 120 μg, and the immunizing adjuvant was 1 / 2 HD AS01 adjuvant. Blood was collected and tested 14 days after the two immunizations, and the evaluation results are shown in the attached Figure 5 (Neutralizing antibody titer against type A virus after RSV vaccine antigen immunization of large-eared white rabbits), and attached Figure 6 (The results of cross-protection neutralizing antibody titer against type B virus after immunizing large-eared white rabbits with 120 μg of RSV vaccine antigen).

[0267] Table 18: Test groups for different doses of RSV antigen

[0268]

[0269] The dose of type A antigen F194 and F196 can be 60μg or 120μg. The neutralizing antibody titer of 60μg is higher than that of 120μg, which shows that the vaccine antigen dose within the range of 60-120μg can stimulate the body to produce a strong immune response. Figure 6 This indicates that 120 μg of type A antigens F194 and F196 have cross-protective immune effects against type B viruses.

[0270] Example 15. Immune evaluation of bivalent vaccine antigens

[0271] A comparative study on the immune evaluation of mice (BALB / c) using a bivalent vaccine and a monovalent vaccine composed of RSV antigens composed of F194 (SEQ ID NO: 14), F196 (SEQ ID NO: 15) of type A and F194 B subtype (SEQ ID NO: 16), F196 B subtype (SEQ ID NO: 17). The detection method was FRNT (type B). Blood was collected and tested 14 days after the second immunization (0 days and 21 days). The immunization method was intramuscular injection of 0.1 ml per mouse. The evaluation results are shown in the attached Figure 7 (Type B virus neutralizing antibody titers after mice (BALB / c) were immunized with RSV bivalent vaccine antigen).

[0272] Table 19: Experimental grouping table for the immunogenicity study of bivalent vaccines

[0273]

[0274] See attached for immunization results Figure 7 The immune data showed that the neutralizing antibody levels of the F194 and F196 bivalent vaccine adjuvant groups were significantly higher than those of the non-adjuvant groups. Numerically, the neutralizing antibody titers of the bivalent vaccine group against subtype B viruses were also higher than those of the monovalent vaccine group and the DS-Cav1 control group.

[0275] Example 16. Structural studies on disulfide bond mutations

[0276] Based on the resolved post [McLellan et al., https: / / doi.org / 10.1128 / JVI.00555-11] and pre [McLellan et al., https: / / doi.org / 10.1126 / science.1234914] crystal structures, the specific sites for the design of disulfide bond mutations were studied to illustrate the design and characteristics of the RSV F protein stabilized in the pre-fusion form of the present invention.

[0277] The following figure shows the RSV F protein before fusion. The amino acid residues at positions 75 and 218 between the two monomers of the F protein (highlighted in light blue in the ribbon diagram) are shown in the attached Figure 8 (In the prefusion conformation of F49(K75C+E218C), two amino acids are separated ), it is expected that the disulfide bonds in the F49(K75C+E218C) construct can lock the recombinant RSV F protein in the prefusion conformation, protect the spacing unchanged, and make the prefusion F protein structure in the trimer form more stable.

[0278] The design of N-type disulfide bond mutations is shown in the figure below. In the ribbon diagram, the changes in the distance between the two amino acids I148C+Y286C, S55C+L188C, H159C+I291C and G151C+I288C in the pre-fusion conformation and post-fusion conformation of the RSV F protein are highlighted in dark blue. Fig. 9 (N-type cysteine ​​substituted RSV F protein in the prefusion conformation of the substitution site is less than ), it is expected that the disulfide bonds in the I148C+Y286C, S55C+L188C, H159C+I291C and G151C+I288C constructs can lock the recombinant RSV F protein in the prefusion conformation, making the prefusion F protein structure in the trimer form more stable.

[0279] The design of class C disulfide bond mutations is shown in the figure below. In the ribbon diagram, the changes in the distance between two amino acids K399C+S485C, S443C+S466C, T323C+I475C, I332C+P480C or F387C+I492C in the pre-fusion conformation and post-fusion conformation of RSV F protein are highlighted in dark blue. Fig.10 (The substitution sites in the prefusion conformation of the RSV F protein with cysteine ​​substitutions in class C are less than ), it is expected that the disulfide bonds in the K399C+S485C, S443C+S466C, T323C+I475C, I332C+P480C or F387C+I492C constructs can lock the recombinant RSV F protein in the prefusion conformation, making the prefusion F protein structure in the trimer form more stable.

[0280] The specific embodiments described above further illustrate the objectives, technical solutions and beneficial effects of the present invention in detail. It should be understood that the above description is only a specific embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.

Claims

1. A recombinant RSV polypeptide comprising a recombinant extracellular domain of RSV F protein corresponding to amino acid residues 26-513 of the wild-type RSV F protein sequence shown in SEQ ID NO: 1, characterized in that Compared to wild-type RSV F protein, the RSV F protein has one or a combination of the following mutations: AN type cysteine ​​substitution mutations, wherein the site of the N type cysteine ​​substitution is between residues 137-216 of the wild-type RSV F protein amino acid sequence, including 1 or 2 pairs of cysteine ​​substitutions; Class BC cysteine ​​substitution mutations, wherein the site of the Class C cysteine ​​substitution is between residues 460-500 of the wild-type RSV F protein amino acid sequence, including 1 or 2 pairs of cysteine ​​substitutions; C. Intermolecular cysteine ​​substitution mutation, wherein the intermolecular cysteine ​​substitution is selected from one or two pairs of V144C+I407C, K75C+E218C, S146C+N460C and A149C+Y458C.

2. The polypeptide of claim 1, wherein the N-type cysteine ​​substitution mutation is selected from one or two pairs of I148C+Y286C, S55C+L188C, H159C+I291C and G151C+I288C.

3. The polypeptide of claim 1, wherein the class C cysteine ​​substitution mutation is selected from one or two pairs of K399C+S485C, S443C+S466C, T323C+I475C, I332C+P480C and F387C+I492C.

4. A recombinant RSV polypeptide comprising a recombinant extracellular domain of RSV F protein, corresponding to amino acid residues 26-513 of the wild-type RSV F protein sequence shown in SEQ ID NO: 1, wherein the recombinant extracellular domain comprises a combination of the following cysteine ​​substitution mutations: A. Intermolecular cysteine ​​substitution mutations are selected from one or two pairs of V144C+I407C, K75C+E218C, S146C+N460C and A149C+Y458C; B, N-type cysteine ​​substitution mutation, one of which is at position 137 to 216 of the F protein; C. Class C cysteine ​​substitution mutations, one of which is located between positions 460 and 500 of the F protein.

5. The polypeptide of claim 4, wherein the one mutation site at positions 137 to 216 of the F protein is one or two pairs selected from I148C+Y286C, S55C+L188C, H159C+I291C and G151C+I288C; wherein the one mutation site at positions 460 to 500 of the F protein refers to K399C+S485C, S443C+S466C, T323C+I475C, I332C+P480C or F387C+I492C.

6. The polypeptide of claim 5, wherein the recombinant extracellular domain comprises a combination of the following cysteine ​​substitution mutations: A, an intermolecular cysteine ​​substitution mutation selected from V144C+I407C and / or K75C+E218C; B. N-type cysteine ​​substitution mutation selected from I148C+Y286C, G151C+I288C or H159C+I291C; C. Class C cysteine ​​substitution mutation selected from F387C+I492C, K399C+S485C or T323C+I475C.

7. A recombinant RSV polypeptide comprising a recombinant extracellular domain of RSV F protein corresponding to amino acid residues 26-513 of the wild-type RSV F protein sequence shown in SEQ ID NO: 1, characterized in that: The recombinant extracellular domain has cysteine ​​mutations K75C+E218C and / or V144C+I407C compared to the wild-type RSV F protein.

8. The polypeptide according to claim 7, characterized in that Compared with wild-type RSV F protein, there are cysteine ​​mutations I148C+Y286C or S55C+L188C.

9. The polypeptide according to claim 7, characterized in that Compared with wild-type RSV F protein, there are cysteine ​​mutations K399C+S485C or F387C+I492C.

10. The polypeptide of claim 7, wherein the recombinant extracellular domain comprises one of the following combinations of cysteine ​​substitution mutations: A, V144C+I407C, K75C+E218C, I148C+Y286C, and F387C+I492C; B, V144C+I407C, I148C+Y286C, S55C+L188C, and F387C+I492C; C. K75C+E218C, I148C+Y286C, T323C+I475C; D. K75C+E218C, I148C+Y286C, F387C+I492C; E. K75C+E218C, I148C+Y286C, K399C+S485C; F, K75C+E218C, G151C+I288C, K399C+S485C; G, K75C+E218C, H159C+I291C, K399C+S485C.

11. A polypeptide as described in any one of claims 1 to 10, wherein the recombinant extracellular domain further comprises a cavity filling mutation, and the cavity filling mutation site is selected from positions 67, 495, 296 and 190 of the wild-type RSV F protein amino acid sequence; preferably, the cavity filling mutation is N67F or N67F+S190V+V296F+V495L.

12. The polypeptide according to claim 11, wherein the recombinant extracellular domain further comprises mutations P102A+I379V+M447V, S46G or G184N that increase the expression amount.

13. The polypeptide of any one of claims 1-10, wherein the recombinant extracellular domain comprises a recombinant F2 domain comprising at least amino acid residues 26-105 of the RSV F protein and a recombinant F1 domain comprising at least amino acid residues 145-513 of the RSV F protein. The polypeptide of claim 13 , wherein the recombinant F2 domain is connected to the recombinant F1 domain directly or through a linker.

15. The polypeptide according to claim 14, wherein the recombinant F2 domain is connected to the recombinant F1 domain via a linker, which means that residues 106-144 of the recombinant extracellular domain of the F protein are replaced by a linker selected from GGPGGS, GAPEPGE or GGSGGSG.

16. The polypeptide of any one of claims 1-15, wherein the C-terminus of the polypeptide comprises a trimerization domain or a multimerization domain.

17. The polypeptide of claim 16, wherein the trimerization domain is a foldon, GCN4 or MTQ domain and the multimerization domain is a ferritin domain.

18. Use of the polypeptide according to any one of claims 1 to 17 in the preparation of a vaccine for preventing RSV infection.

19. A vaccine for preventing RSV infection, comprising the polypeptide of any one of claims 1-17; the vaccine provides protection against infection by at least one of RSV subtype A and / or subtype B.

20. The vaccine for preventing RSV infection according to claim 19, comprising an adjuvant in the form of liposomes.

21. The vaccine for preventing RSV infection as claimed in claim 20, wherein the components of the adjuvant in the form of liposomes include MPL, QS-21 and cholesterol.

Citation Information

Cited By

  • Trimer motif and application thereof in expression of RSV trimer protein

    CN120607592A

  • Mutant of RSV pre-fusion F protein and application thereof

    CN121342930A

  • Respiratory syncytial virus f protein mutant and use thereof

    WO2026158514A1